Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02890069
Title A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

colorectal cancer

lung non-small cell carcinoma

triple-receptor negative breast cancer

Therapies

LCL161 + Spartalizumab

Everolimus + Spartalizumab

Panobinostat + Spartalizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.